Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near termThree patent applications are pending, including two method
Oncolytics got new patents protecting their cancer medicine until 2044. This gives the company longer to be the only one selling it, which matters when thinking about the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.